NRAS-MUTANT SOLID TUMORS

Clinical trials for NRAS-MUTANT SOLID TUMORS explained in plain language.

Never miss a new study

Get alerted when new NRAS-MUTANT SOLID TUMORS trials appear

Sign up with your email to follow new studies for NRAS-MUTANT SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New targeted drug hopes to shrink Hard-to-Treat melanoma

Disease control Recruiting now

This early-stage study tests a new drug called RLY-8161 in people with advanced melanoma or other solid tumors that have a specific NRAS gene mutation. The main goals are to find a safe dose and see if the drug can shrink tumors. About 35 participants will take the drug by mouth,…

Matched conditions: NRAS-MUTANT SOLID TUMORS

Phase: PHASE1 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control

Last updated May 26, 2026 11:24 UTC

NRAS-MUTANT SOLID TUMORS

Get alerted when new NRAS-MUTANT SOLID TUMORS trials appear

New targeted drug hopes to shrink Hard-to-Treat melanoma